Human papillomavirus type 11 major capsid protein L1 (HPV11 L1) (HPV11 L1)

Human papillomavirus type 11 (HPV11) major capsid protein L1 is the primary structural component of the HPV11 virion and a critical target for prophylactic intervention (UniProt P03103) [1]. This protein self-assembles into pentamers called capsomeres, which further organize into virus-like particles (VLPs) that mimic the native virus structure (NCBI) [2]. The conformational epitopes presented on the surface of these VLPs are essential for inducing a potent neutralizing antibody response (Christensen et al., 2001) [3]. HPV11 is a low-risk genotype predominantly responsible for genital warts (condyloma acuminata) and recurrent respiratory papillomatosis (RRP) (CDC) [4]. Prophylactic vaccines, such as the quadrivalent and nonavalent HPV vaccines, utilize recombinant HPV11 L1 VLPs to elicit antibodies that recognize these specific 3D epitopes (FDA) [5]. These antibodies prevent viral infection by blocking the attachment of the virus to host cell heparan sulfate proteoglycans and subsequent internalization into basal epithelial cells [3, 5]. Because these epitopes are conformational, their structural integrity is paramount for the efficacy of the vaccine and the accuracy of diagnostic serological assays [3].

Other names

HPV11 L1Human papillomavirus 11 L1 proteinL1 capsid protein of HPV-11Major capsid protein L1 [Human papillomavirus type 11]

The primary mechanism involves the induction of humoral immunity, specifically the production of high-titer neutralizing antibodies that bind to surface-exposed conformational epitopes on the L1 protein. This binding sterically hinders the virus from interacting with host cell receptors, such as heparan sulfate proteoglycans, thereby preventing viral entry and subsequent infection of the basal epithelium (Christensen et al., 2001; FDA) [3, 5].